Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 17;17(1):276.
doi: 10.1186/s12885-017-3269-6.

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

Alessandro Broccoli  1 , Beatrice Casadei  2 , Vittorio Stefoni  2 , Cinzia Pellegrini  2 , Federica Quirini  2 , Lorenzo Tonialini  2 , Alice Morigi  2 , Miriam Marangon  2 , Lisa Argnani  2 , Pier Luigi Zinzani  2
Affiliations

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

Alessandro Broccoli et al. BMC Cancer. .

Abstract

Background: The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least two decades.

Methods: Our single centre experience in the treatment of 98 de novo PMLBCL patients over the last 20 years is reviewed. All patients received MACOP-B chemotherapy. Thirty-seven received both rituximab and mediastinal radiotherapy; 30 were irradiated after chemotherapy, although not receiving rituximab and 20 received rituximab without radiotherapy consolidation. Eleven patients received chemotherapy only.

Results: Sixty-one (62.2%) patients achieved a complete response after MACOP-B (with or without rituximab); among the 27 (27.6%) partial responders, 21 obtained a complete response after radiotherapy. At the end of their scheduled treatment, 82 patients (83.7%) had a complete and 6 a partial response (6.1%). Eleven patients relapsed within the first 2 years of follow-up. The 17-year overall survival is 72.0% (15 patients died); progression-free and disease-free survival are 67.6% and 88.4%, respectively. A statistically significant difference in overall and progression-free survival was noted among treatment groups, although no disease-free survival difference was documented.

Conclusions: Our data indicate that a third-generation regimen like MACOP-B could be considered a suitable first-line treatment. Mediastinal consolidation radiotherapy impacts on survival and complete response rates and remains a good strategy to convert partial into complete responses. Data suggest that radiotherapy may be avoided in patients obtaining a complete response after (immuno)chemotherapy, but this requires confirmation with further ad hoc studies.

Keywords: Chemotherapy; MACOP-B; primary mediastinal lymphoma; radiotherapy; rituximab.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival (a), progression-free survival (b) and disease-free survival (c) curves plotted for the entire population on study. Subgroup survival analysis is shown underneath: overall survival (d), progression-free survival (e) and disease-free survival (f). Solid black line is for subgroup 1, dashed black line is for subgroup 2, solid grey line is for subgroup 3 and dashed black line is for subgroup 4. Vertical axis shows survival percentages
Fig. 2
Fig. 2
Overall survival (a) and disease-free survival (b) curves plotted according to the administration of rituximab with chemotherapy. Vertical axis shows survival percentages. R rituximab; CHT chemotherapy
See this image and copyright information in PMC

References

    1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392. - PubMed
    1. Banks PM, Warnke RA, et al. Mediastinal (thymic) large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 175–176.
    1. Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol. 2008;26:171–178. doi: 10.1002/hon.858. - DOI - PubMed
    1. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391. doi: 10.1016/S1470-2045(06)70664-7. - DOI - PubMed
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources